Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group.

Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613.

PMID:
22127708
[PubMed - indexed for MEDLINE]
Free Article
2.

Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus.

Biesen R, Dähnrich C, Rosemann A, Barkhudarova F, Rose T, Jakob O, Bruns A, Backhaus M, Stöcker W, Burmester GR, Schlumberger W, Egerer K, Hiepe F.

Arthritis Res Ther. 2011 Feb 10;13(1):R26. doi: 10.1186/ar3250.

PMID:
21329504
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group.

Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.

PMID:
21296403
[PubMed - indexed for MEDLINE]
4.

Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study.

Petri M, Singh S, Tesfasyone H, Malik A.

J Rheumatol. 2009 Nov;36(11):2476-80. doi: 10.3899/jrheum.090019. Epub 2009 Oct 15.

PMID:
19833757
[PubMed - indexed for MEDLINE]
5.

Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic.

Nasiri S, Karimifar M, Bonakdar ZS, Salesi M.

Rheumatol Int. 2010 Nov;30(12):1605-9. doi: 10.1007/s00296-009-1201-3. Epub 2009 Oct 7.

PMID:
19809816
[PubMed - indexed for MEDLINE]
6.

Novel evidence-based systemic lupus erythematosus responder index.

Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698.

PMID:
19714615
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.

PMID:
19714604
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The socioeconomic burden of SLE.

Lau CS, Mak A.

Nat Rev Rheumatol. 2009 Jul;5(7):400-4. doi: 10.1038/nrrheum.2009.106. Epub 2009 Jun 9. Review.

PMID:
19506585
[PubMed - indexed for MEDLINE]
9.

Systemic lupus erythematosus.

Rahman A, Isenberg DA.

N Engl J Med. 2008 Feb 28;358(9):929-39. doi: 10.1056/NEJMra071297. Review. No abstract available.

PMID:
18305268
[PubMed - indexed for MEDLINE]
10.

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, Isenberg D, Kallenberg CG, Khamashta M, Piette JC, Schneider M, Smolen J, Sturfelt G, Tincani A, van Vollenhoven R, Gordon C, Boumpas DT; Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Ann Rheum Dis. 2008 Feb;67(2):195-205. Epub 2007 May 15.

PMID:
17504841
[PubMed - indexed for MEDLINE]
Free Article
11.

Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.

Halpern WG, Lappin P, Zanardi T, Cai W, Corcoran M, Zhong J, Baker KP.

Toxicol Sci. 2006 Jun;91(2):586-99. Epub 2006 Mar 3.

PMID:
16517838
[PubMed - indexed for MEDLINE]
Free Article
12.

Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus.

van den Berg L, Nossent H, Rekvig O.

Clin Rheumatol. 2006 May;25(3):347-52. Epub 2005 Nov 23.

PMID:
16328091
[PubMed - indexed for MEDLINE]
13.

The role of biomarkers in the assessment of lupus.

Merrill JT, Buyon JP.

Best Pract Res Clin Rheumatol. 2005 Oct;19(5):709-26. Review.

PMID:
16150399
[PubMed - indexed for MEDLINE]
14.

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.

Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, Sturm B, Poortman C, Minter RR, Dobson CL, Williams E, Carmen S, Smith R, Roschke V, Hilbert DM, Vaughan TJ, Albert VR.

Arthritis Rheum. 2003 Nov;48(11):3253-65.

PMID:
14613291
[PubMed - indexed for MEDLINE]
Free Article
15.

Accurately describing changes in disease activity in Systemic Lupus Erythematosus.

Gladman DD, Urowitz MB, Kagal A, Hallett D.

J Rheumatol. 2000 Feb;27(2):377-9.

PMID:
10685800
[PubMed - indexed for MEDLINE]
16.

Immunologic factors and clinical activity in systemic lupus erythematosus.

Schur PH, Sandson J.

N Engl J Med. 1968 Mar 7;278(10):533-8. No abstract available.

PMID:
4866347
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk